top of page
Browse by category
Search
Fractyl unveils promising preclinical data demonstrating safety and feasibility of local delivery of RJVA-001 Rejuva Smart GLP-1 Pancreatic Gene Therapy
Fractyl Health has presented new data from its preclinical Rejuva Smart GLP-1 pancreatic gene therapy program in a poster titled,...
Fractyl’s Rejuva platform demonstrates potent and durable effects of a single dose of a human GLP-1 pancreatic gene therapy transgene vs semaglutide for diabetes and obesity
Fractyl Health has revealed promising new preclinical findings for the first clinical candidate in its Rejuva pancreatic gene therapy...
GLP-1-based pancreatic gene therapy maintained weight loss after semaglutide withdrawal in rodents
Fractyl Health has revealed that preclinical findings from its Rejuva gene therapy platform, presented at the World Congress Insulin...
Fractyl expands ERASE Task Force to study underlying GLP-1-based pancreatic gene therapy for T2DM
Fractyl Health has expanded an academic-industry scientific partnership charged with advancing research on the role of the gut and...
Browse by tag
bottom of page